HERON THERAPEUTICS, INC. /DE/ Quarterly Debt-to-equity in % from Q1 2012 to Q4 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Heron Therapeutics, Inc. /De/ quarterly Debt-to-equity history and growth rate from Q1 2012 to Q4 2024.
  • Heron Therapeutics, Inc. /De/ Debt-to-equity for the quarter ending December 31, 2024 was -712 %, a 18.8% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2024 -712 +165 +18.8% Dec 31, 2024
Q3 2024 -704 +786 +52.8% Sep 30, 2024
Q2 2024 -765 +5.77K +88.3% Jun 30, 2024
Q1 2024 -746 -35.2K -102% Mar 31, 2024
Q4 2023 -877 -3.5K -133% Dec 31, 2023
Q3 2023 -1.49K -2.46K -253% Sep 30, 2023
Q2 2023 -6.53K -7.02K -1428% Jun 30, 2023
Q1 2023 34.5K +34.2K +13626% Mar 31, 2023
Q4 2022 2.62K +2.47K +1666% Dec 31, 2022
Q3 2022 971 +872 +874% Sep 30, 2022
Q2 2022 492 +424 +627% Jun 30, 2022
Q1 2022 251 +207 +473% Mar 31, 2022
Q4 2021 148 +111 +295% Dec 31, 2021
Q3 2021 99.7 +67.3 +208% Sep 30, 2021
Q2 2021 67.7 +35.9 +113% Jun 30, 2021
Q1 2021 43.8 +11.8 +36.7% Mar 31, 2021
Q4 2020 37.6 +5.4 +16.8% Dec 31, 2020
Q3 2020 32.4 +0.69 +2.18% Sep 30, 2020
Q2 2020 31.8 Jun 30, 2020
Q1 2020 32.1 Mar 31, 2020
Q4 2019 32.2 Dec 31, 2019
Q3 2019 31.7 Sep 30, 2019
Q4 2017 99.9 Dec 31, 2017
Q3 2017 172 Sep 30, 2017
Q2 2017 197 Jun 30, 2017
Q1 2012 19.7 Mar 31, 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.